Featured in NEJM Journal Watch: Infliximab or Adalimumab in Crohn Disease? — Physician’s First Watch
Featured in NEJM Journal Watch: Infliximab or Adalimumab in Crohn Disease?
By the NEJM Journal Watch Editors
In a retrospective cohort study of U.S. Medicare patients, rates of persistent drug use at week 26, surgery, and hospitalization were similar with either agent. The study, which appears in Clinical Gastroenterology and Hepatology, examined data from some 2300 new users of the drugs between 2006 and 2010.